VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

For more information on Age-Related Macular Degeneration go to the NHS website, external. If you've had a diagnosis, in addition to support from your specialist, you may find it useful to use ...

The team enrolled 19 patients over age 50 with advanced wet AMD and divided subjects into five groups that received different doses of the gene. “Even at the highest dose, the treatment was quite safe ...

On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming ...

Faricimab helped improve vision in previously untreated patients with neovascular age-related macular degeneration, according ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a ...